Skip to main content

Table 2 Significant associations between the tested polymorphisms and analysed phenotypes

From: ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients

Gene

SNP

Phenotypes

Model of inheritance or MAFa

OR (95% CI)

P-value

Sample power (%)

BADGE class for genetic association

RXRA

rs749759

MI vs without MI

Recessive

2.22 (1.28–3.84)

0.004

75.6

Fifth

RXRA

rs10776909

MI vs without MI

Recessive

3.08 (1.60–5.93)

0.0004

85.1

Fourth

 

Additive

3.17 (1.63–6.18)

0.0004

99.9

Fourth

ENHO

rs2281997

Dyslipidaemia vs non-dyslipidaemia

by K/DOQI criteria

Recessive

2.87 (1.65–4.99)

0.0001

99.9

Third/Fourth

 

Additive

3.16 (1.80–5.57)

0.00003

99.9

Third

 

MAF (T vs. C allele)

1.49 (1.21–1.84)

0.0002

 

Fourth

ENHO

rs2281997

Hyper-LDL cholesterolaemic dyslipidaemia

vs non-dyslipidaemia by K/DOQI criteria

Dominant

1.55 (1.14–2.11)

0.006

78.3

Fifth

 

Recessive

3.10 (1.71–5.63)

0.0001

86.5

Third/Fourth

 

Additive

3.53 (1.91–6.53)

0.00003

99.9

Third

 

MAF (T vs. C allele)

1.59 (1.25–2.02)

0.0002

 

Fourth

ENHO

rs2281997

LDL cholesterol ≥100 mg/dL

vs LDL cholesterol < 100

Dominant

1.43 (1.10–1.87)

0.009

74.3

Fifth

 

Recessive

2.18 (1.32–3.60)

0.002

75.0

Fifth/Fourth

 

Additive

2.44 (1.45–4.10)

0.0006

99.9

Fourth

 

MAF (T vs. C allele)

1.43 (1.16–1.76)

0.0007

 

Fourth

ENHO

rs2281997

Atherogenic dyslipidaemia

vs without atherogenic dyslipidaemia

dominant

0.65 (0.50–0.85)

0.002

88.7

Fifth/Fourth

 

additive

0.49 (0.29–0.81)

0.005

99.9

Fifth

 

MAF (T vs. C allele)

0.70 (0.57–0.86)

0.0007

 

Fourth

  1. Abbreviations: MAF minor allele frequency, MI myocardial infarction
  2. a MAF is referred to the frequency of the respective major allele. The minor allele is underlined
  3. Detailed analyses for all tested associations are shown in the Additional file 1